SCHEMBL14919172

SCHEMBL14919172

CN(C)C(=O)c1ccc(C(=O)O)c(-c2cc[nH]n2)c1-c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
ALDH1A1 P00352 1/20 0.38
RAB9A P51151 1/20 0.37
KEAP1 Q14145 1/20 0.36
ACLY P53396 1/20 0.35
ATR Q13535 1/20 0.34
KDM4E B2RXH2 2/20 0.33
GLA P06280 1/20 0.33
LDHA P00338 1/20 0.33
POLB P06746 1/20 0.33
KDM4A O75164 1/20 0.33
TP53 P04637 1/20 0.33
DHODH Q02127 1/20 0.32
FABP4 P15090 2/20 0.32
MDM2 Q00987 1/20 0.32
FABP3 P05413 1/20 0.32
FABP5 Q01469 1/20 0.32
NCOA1 Q15788 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14919171 0.79 MEN1 (0.51) MEN1KMT2ASMN1; SMN2ALDH1A1RAB9A
SCHEMBL16037020 0.79 ALDH1A1 (0.37) ALDH1A1ACLYLDHATP53DHODH
SCHEMBL16038154 0.76 FBP1 (0.41) MEN1KMT2ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL16038157 0.76 FBP1 (0.41) MEN1KMT2ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL16039157 0.76 DHODH (0.38) DHODH
SCHEMBL14918727 0.74 HNF4A (0.49) MEN1KMT2ASMN1; SMN2ALDH1A1RAB9A
SCHEMBL14918728 0.74 HNF4A (0.53) MEN1KMT2ASMN1; SMN2ALDH1A1RAB9A
SCHEMBL14918609 0.74 ALDH1A1 (0.47) KMT2ASMN1; SMN2ALDH1A1KDM4EPOLB
SCHEMBL29073837 0.74 ALDH1A1 (0.41) SMN1; SMN2ALDH1A1KEAP1KDM4E
SCHEMBL332581 0.70 ALDH1A1 (0.57) SMN1; SMN2ALDH1A1KDM4EFABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140275049-A1 SUBSTITUTED PYRAZOLE ANALOGS As RAR ANTAGONISTS ELI LILLY AND COMPANY 2014-09-18 US disclosed
WO-2013066640-A1 SUBSTITUTED PYRAZOLE ANALOGUES AS RAR ANTAGONISTS ELI LILLY AND COMPANY (US) 2013-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275049-A1 SUBSTITUTED PYRAZOLE ANALOGS As RAR ANTAGONISTS RARB, RARA, RARG MEN1 4858/4885KMT2A 2643/4885SMN1; SMN2 3574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.